Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tuberkuloosi, monilääkeresistenssi - mykobakteerilÄÄkkeet - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Suomi - suomi - Fimea (Suomen lääkevirasto)

schering oy - propyphenazonum,ethenzamidum,coffeinum,codeini phosphas - tabletti - etentsamidi, yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - cisplatinum - infuusiokuiva-aine - sisplatiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - cisplatinum - infuusiokonsentraatti - 0.5 mg/ml - sisplatiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - silmätautien - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Euroopan unioni - suomi - EMA (European Medicines Agency)

stada arzneimittel ag - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Euroopan unioni - suomi - EMA (European Medicines Agency)

midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Euroopan unioni - suomi - EMA (European Medicines Agency)

viatris limited - aflibersepti - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - silmätautien - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxo group ltd - retapamuliinin - impetigo; staphylococcal skin infections - antibiootit ja kemoterapeuttiset aineet dermatologiseen käyttöön - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. , ks. kohdat 4. 4 ja 5. 1 tärkeää tietoa kliinisen toiminnan retapamuliini vastaan erilaisia staphylococcus aureus. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - ranibitsumabi - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - silmätautien - lucentis on tarkoitettu aikuisille:hoito neovaskulaarisen (kostean) ikään liittyvä silmänpohjan rappeuma (amd)hoito näkövamman vuoksi suonikalvon uudissuonittumisesta (cnv)hoito näkövamman vuoksi diabeettinen makulaturvotus (dme)hoidossa näön huonontuminen makulaarisen ödeeman takia, toissijainen verkkokalvon laskimotukos (branch rvo tai keski-rvo).